Difference between revisions of "Apalutamide (Erleada)"
Jump to navigation
Jump to search
m (PeterYang moved page ARN-509 to Apalutamide (ARN-509): updated name) |
m |
||
| Line 1: | Line 1: | ||
=Mechanism of action= | =Mechanism of action= | ||
Competitive androgen receptor (AR) inhibitor | Competitive androgen receptor (AR) inhibitor | ||
| + | |||
| + | =Preliminary data= | ||
| + | ==[[Prostate cancer]]== | ||
| + | # Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. Epub 2017 Feb 17. [https://www.ncbi.nlm.nih.gov/pubmed/28213364 PubMed] | ||
| + | # Rexer H, Graefen M. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO]. Urologe A. 2017 Feb;56(2):243-244. German. [https://www.ncbi.nlm.nih.gov/pubmed/28144693 PubMed] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Oral medications]] | ||
[[Category:Endocrine therapy]] | [[Category:Endocrine therapy]] | ||
Revision as of 15:23, 5 October 2017
Mechanism of action
Competitive androgen receptor (AR) inhibitor
Preliminary data
Prostate cancer
- Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. Epub 2017 Feb 17. PubMed
- Rexer H, Graefen M. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO]. Urologe A. 2017 Feb;56(2):243-244. German. PubMed